No results found

Check the spelling or try searching for a more general term.

AAO 2018

AAO 2018

Ellex invites you to join us in Chicago for the 2018 meeting of the American Association of Ophthalmology (AAO), 27-30 October 2018. Visit the Ellex Exhibit #1044 to discuss the proactive care of your glaucoma patients, or the role of Ellex’s proprietary Reflex Technology™ in the treatment of symptomatic floater patients. Ellex will also highlight the role of its breakthrough 2RT® Retinal Rejuvenation Therapy for early age-related macular degeneration (AMD).

Eyeworld Symposium

Earlier Intervention and Treatment: from Glaucoma to Retina

Join your colleagues and a panel of experts across the disciplines of glaucoma and retinal disease for an interactive panel discussion hosted by EyeWorld. Taking place on Sunday morning in downtown Chicago, the symposium will address the opportunities for earlier intervention in the diagnosis of retinal disease and glaucoma – and how this translates to better patient care. The synergies of SLT and ABiC™ in the glaucoma treatment armamentarium will also be addressed, along with the emerging role of 2RT® as an interventional treatment for early AMD.

Proprietary diagnostic and treatment technologies from Diopsys and Ellex will also spotlighted during the panel discussion.

Speakers

John Marshall
PhD, FMedSci, FRCPath, FRCOphth (Hon) (UK)
Mark Latina
MD (USA)
Mahmoud A. Khaimi
MD (USA)
Steven Silverstein
MD (USA)

SUNDAY, 28 OCTOBER
7:00 – 8:00am
Venue:

Hilton Chicago International
720 S Michigan Ave
Room: North Ballroom

Moderator:
David Lubeck, MD (USA)

Register your interest Download the invitation

Glaucoma Events

MIGS Meet the Expert / Wet Lab

Join us at the Ellex Exhibit #1044 to meet a panel of ABiC™ to discuss their clinical tips and surgical pearls for ABiC™, the next step in canal-based glaucoma surgery. A key highlight of these sessions will be hands-on Wet Labs featuring Ellex’s iTrack™ surgical system.  

Speakers

Mahmoud A. Khaimi
MD (USA)
David Lubeck
MD (USA)
David Richardson
MD (USA)
Constance Okeke
MD, (USA)

SATURDAY, 27 OCTOBER

SESSION 1:
10:00am – 11:00am
Mahmoud A. Khaimi, MD
David Lubeck, MD

SESSION 2:
3:00pm – 4:00pm
David Richardson, MD

SUNDAY, 28 OCTOBER

SESSION 1:
10:00am – 11:00am
Mahmoud A. Khaimi, MD
David Lubeck, MD

SESSION 2:
3:00pm – 4:00pm
David Richardson, MD
Mahmoud A. Khaimi, MD

MONDAY, 29 OCTOBER

SESSION 1:
10:00am – 11:00am
Mahmoud A. Khaimi, MD

SESSION 2:
3:00pm – 4:00pm
David Richardson, MD
David Lubeck, MD

Register your interest

Note: these sessions are not affiliated with the official program of the AAO 2018.

Speaker Central

Join us for a Speaker Central Session at the Ellex Exhibit #1044 to hear a panel of leading SLT and MIGS practitioners debunk some of the myths surrounding the use of SLT and ABiC™ in clinical practice.

Speakers

Mark J. Gallardo
MD (USA)
Nathan Radcliffe
MD (USA)
Constance Okeke
MD, (USA)
David Richardson
MD (USA)
David Lubeck
MD (USA)

SATURDAY, 27 October

SESSION 1:
10:30am – 11:00am
Mark Gallardo, MD
Nathan Radcliffe, MD
Constance Okeke, MD

SESSION 2:
3:00pm – 3:30pm
Mark Gallardo, MD
David Richardson, MD
David Lubeck, MD

SUNDAY, 28 October

SESSION 1:
10:30am – 11:00am
Mark Gallardo, MD
Nathan Radcliffe, MD
David Richardson, MD

SESSION 2:
3:00pm – 3:30pm
Mark Gallardo, MD
David Richardson, MD
David Lubeck, MD

Register your interest

Note: these sessions are not affiliated with the official program of the AAO 2018

MIGS Skills Transfer Lab: MIGS Devices and Incisional Techniques

ABiC™ experts Mahmoud Khaimi, MD, David Richardson, MD, and David Lubeck, MD will host a hands-on skills transfer lab during AAO 2018. Refer below for time and location details:

Speakers

Mahmoud A. Khaimi
MD (USA)
David Richardson
MD (USA)
David Lubeck
MD (USA)

MONDAY, 29 OCTOBER

SESSION 1:
LAB133A
8:00am – 9:30am

SESSION 2:
LAB133B
10:30am – 12:00pm

VENUE:
Congress Center

Learn more (LAB133A) Learn more (LAB133B)

ABiC™ Physician Lunch

Join your colleagues and leading ABiC™ expert Mahmoud Khaimi, MD (USA), Dean McGee Eye Institute, for an intimate discussion over lunch to address the role of ABiC™, including its adjunctive role with other MIGS options. The synergies between ABiC™ and SLT will also be discussed.

Speakers

Mahmoud A. Khaimi
MD (USA)

DATE:
Saturday, 27 October

TIME:
1:00pm – 2:00pm

VENUE:
TBC

SPEAKER:
Mahmoud Khaimi, MD (USA)

Note: this event is not affiliated with the official program of the AAO 2018.

Proactive Glaucoma Care

Ellex is at the vanguard of working with physicians to transform outcomes and quality of life for patients with glaucoma. Our leading edge SLT Selective Light Therapy and ABiC™ – our restorative solution for minimally invasive glaucoma surgery, performed with the iTrack™ surgical system – offer the ability to intervene earlier in the treatment of glaucoma, and to treat across the full spectrum of the disease, and thereby enable significant numbers of patients to minimize or obviate the need for medications to control their glaucoma.

At Ellex, we're proud to be helping to shift the paradigm towards proactive glaucoma care. Visit the Ellex exhibit #1044 to learn more.

MIGS from Ellex

ABiC™ re-establishes the eye’s natural outflow system by accessing, catheterizing and viscodilating the trabecular meshwork, Schlemm’s canal, and the distal outflow system. It is the only ab-interno minimally invasive glaucoma surgery currently available that comprehensively addresses blockages in the collector channels, flushing the outflow channels without damaging tissue and without leaving behind a stent or shunt. Intuitive and efficient, ABiC™ can be performed as a stand-alone procedure, or it can be combined with cataract surgery. ABiC™ can also be used in conjunction with other MIGS devices or treatments — and, as an atraumatic procedure, it does not preclude future treatment options.

I have been a practicing glaucoma specialist for over 10 years. The introduction of ABiC has completely changed my glaucoma treatment paradigm. Not only has ABiC proven itself to be highly effective in lowering IOP and reducing medication dependence, it also offers an excellent safety profile. There is no manipulation of the conjunctiva, and the post-op recovery resembles that of cataract surgery.

Mahmoud A. Khaimi, MD
Dean McGee Eye Institute, University Of Oklahoma

SLT from Ellex

Ellex’s proprietary SLT technology delivers superior energy control, a sharp-edged aiming beam and the industry’s fastest firing rate of three shots per second. It's a capability that's being used every day by thousands of physicians around the world to visualize the trabecular meshwork in greater detail, and to perform procedures faster and with improved accuracy, delivering better patient outcomes - reliably, accurately and safely.

The safety profile of SLT is so great, I would argue that it's actually a safer first option than many of the medications.

David D. Richardson, MD
San Marino Eye

My treatment paradigm is to go to SLT as primary therapy, and then use a MIGS procedure like ABiC with the iTrack after that. If the disease progresses, my next steps would be perhaps SLT again, and then maybe some other MIGS, pushing back filtering and tube surgeries to later stages. In this paradigm, medication has fallen to an adjunct in between those treatment stages.

Mahmoud A. Khaimi, MD
Dean McGee Eye Institute, University Of Oklahoma

Floater Events

Meet the LFT Experts

Join us at the Ellex Exhibit #1044 to meet a panel of leading LFT experts, including LFT pioneer Dr. Paul I. Singh (USA), during a series of “Meet the Expert” sessions. Having performed more than 3000 LFT procedures using Ellex’s proprietary Reflex Technology, Dr. Singh is an expert in the treatment of symptomatic floater patients. Join the panel daily to hear their surgical pearls and clinical tips, including the benefits of Reflex Technology™ for laser-based floater treatment.

Speakers

Paul Singh
MD (USA)
Karl Stonecipher
MD (USA)
Roxana Fulga
MD (Germany)

SATURDAY, 27 October

SESSION 1:
10:00am – 11:00am
Paul I. Singh, MD
Karl Stonecipher, MD

SESSION 2:
3:00pm – 4:00pm
Paul I. Singh, MD
Roxana Fulga, MD

SUNDAY, 28 October

SESSION 1:
10:00am – 11:00am
Paul I. Singh, MD
Karl Stonecipher, MD

SESSION 2:
3:00pm – 4:00pm
Paul I. Singh, MD
Roxana Fulga, MD

MONDAY, 29 October

SESSION 1:
10:00am – 11:00am
Paul I. Singh, MD
Karl Stonecipher, MD

SESSION 2:
3:00pm – 4:00pm
Paul I. Singh, MD
Roxana Fulga, MD

Register your interest

Note: these sessions are not affiliated with the official program of the AAO 2018.


Speaker Central

Join us for a Speaker Central Session at the Ellex Exhibit #1044 to hear a panel of leading LFT practitioners address some of the misconceptions regarding laser-based floater treatment.

Speakers

Paul Singh
MD (USA)
Karl Stonecipher
MD (USA)
Ivan Mac
MD (USA)
Netan Choudhry
MD (Canada)
Andrzej Dmitriew
MD (Poland)

SATURDAY, 27 October

SESSION 1:
11:30am – 12:00pm
Paul I. Singh, MD
Karl G. Stonecipher, MD
Ivan Mac, MD

SESSION 2:
3:00pm – 4:00pm
Paul I. Singh, MD
Netan Choudhry, MD

SUNDAY, 28 October

SESSION 1:
11:30am – 12:00pm
Paul I. Singh, MD
Karl G. Stonecipher, MD
Ivan Mac, MD

SESSION 2:
3:00pm – 4:00pm
Paul I. Singh, MD
Netan Choudhry, MD
Andrzej Dmitriew, MD

Register your interest

Note: these sessions are not affiliated with the official program of the AAO 2018.


Instructional Course: LFT

A Comprehensive Review of Modern Laser Floater Treatment

Join Ellex and leading LFT experts during AAO 2018 to discuss practical tips and treatment pearls for the treatment of symptomatic floater patients with Ellex's proprietary Reflex Technology.

Speakers

Paul Singh
MD (USA)
Roxana Fulga
MD (Germany)
Andrzej Dmitriew
MD (Poland)
Karl Stonecipher
MD (USA)

TUESDAY, 30 OCTOBER

TIME:
9:00am – 11:15am

COURSE NUMBER:

626

VENUE:
Congress Centre

ROOM:
N137

Find out more (#626)

Note: this event is affiliated with the official program of the AAO 2018.

Reimbursement and Coding Update, LFT

Corcoran Consulting will be available at the Ellex Exhibit #1044 at the session times listed below to present recent updates to coding and reimbursement for Laser Floater Treatment, LFT. Make sure to speak with the team from Corcoran Consulating to to better understand how to make LFT work for your practice – as well as for your patients. 

Speakers

Paul M. Larson
MBA, MMSc, COMT, COE, CPC, CPMA

SATURDAY, 27 October

SESSION 1:
3:00PM - 4:00pm
Paul M. Larson, MBA, MMSc, COMT, COE, CPC, CPMA

MONDAY, 29 October

SESSION 1:
10:00am - 11:00am
Paul M. Larson, MBA, MMSc, COMT, COE, CPC, CPMA

Register your interest

LFT from Ellex

Ellex was the first company to pioneer a laser designed specifically for the treatment of floaters. Our Reflex Technology™ platform features True Coaxial Illumination™ (TCI), on and off-axis modes, a precise aiming beam and a superior energy beam profile. It’s an approach that maximizes focusing accuracy and provides a safe and highly effective tool for the treatment of vitreous opacities.

I adopted laser floater treatment for the symptomatic floater patients just over three years ago. More than 3,000 procedures later, I have been astounded by the positive effect it has had on my patients. I now also fully appreciate the negative impact floaters can have on patients’ quality of life. When looking at the results in my own clinic, more than 90% of patients indicate that they are satisfied with their improvement in daily visual functioning as a result of undergoing the procedure.”

Paul I. Singh, MD
Eye Centers of Racine and Kenosha, USA

2RT Events

Meet the 2RT Expert

Join us at the Ellex Exhibit #1044 to meet 2RT® clinician Prof. Andrea Cusumano. Prof. Cusumano will provide his clinical insight into the mechanism of 2RT® and its clinical application as an intervention for early age-related macular degeneration (AMD).

Speakers

Andrea Cusumano
MD, PhD (Italy)

MONDAY, 29 October

SESSION 1:
10:00am – 11:00am
Andrea Cusumano, MD

SESSION 2:
3:00pm – 4:00pm
Andrea Cusumano, MD

Register your interest

Note: this event is not affiliated with the official program of the AAO 2018.

Speaker Central

Join us for a Speaker Central Session at the Ellex Exhibit #1044 to hear leading 2RT® researchers and practitioners address some of the misconceptions surrounding 2RT®  Retinal Rejuvenation Therapy as an intervention for early AMD.

Speakers

Andrea Cusumano
MD, PhD (Italy)
Netan Choudhry
MD (Canada)

SATURDAY, 27 October

SESSION 2:
2:30pm – 3:00pm
Netan Choudhry, MD

SUNDAY, 28 October

SESSION 1:
10:00am – 10:30am
Andrea Cusumano, MD

SESSION 2:
2:30pm – 3:00pm
Andrea Cusumano, MD
Netan Choudhry, MD

Register your interest

Note: these sessions are not affiliated with the official program of the AAO 2018.

2RT from Ellex

Retinal Rejuvenation Therapy, 2RT®, stimulates a biological healing process that results in cellular rejuvenation, renewing the entire transport mechanism of the retina and improving the hydraulic conductivity of Bruch’s membrane. This rejuvenation process preserves or improves functional vision and reduces disease progression — without causing collateral damage to the overlying photoreceptor rods and cones of the retina. 2RT® offers the potential to intervene earlier in the treatment of AMD before significant vision loss has occurred to slow the degeneration process.

The major difference between 2RT nanopulse laser therapy and conventional lasers is the difference in the responses in the patient. With a conventional laser, you will always get some collateral damage to the light sensitive cells. With 2RT being this disruptive mechanism we have no collateral damage and therefore we get the therapeutic effect with none of the collateral effects of damage to the light sensitive cells.”

JOHN MARSHALL
Frost Professor of Ophthalmology, Institute of Ophthalmology, University College, Moorfields Eye Hospital, UK

Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. The material presented herein may include the views or recommendations of third parties and does not necessarily reflect the views of Ellex Medical Pty Ltd.

2RT® has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.

2RT® has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macula Edema (CSME).

Welcome to Ellex Global. Continue to Ellex USA at ellex.comus/
Let's go!
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More